NEW YORK(GenomeWeb) – Molecular diagnostics firm Biofortuna has raised £1.5 million ($2.2 million) in its latest private funding round, the company announced today.
Based in the UK, Biofortuna offers contract in vitro diagnostics development, lyophilization, and stabilization services in its FDA- and ISO13485-approved facilities.
The company also manufactures its own molecular diagnostic products for the transplantation, disease identification, and pharmacogenetic markets. Its SSPgo kits for HLA typing are distributed by Abbott and received 510(k) clearance from the US Food and Drug Administration last year.
The new funding will support development of a portfolio of molecular diagnostic assays that address complex genotyping issues, the company said in a statement. It will also support further investment in Biofortuna's freeze-drying production capability to meet projected growth.
The company recently expanded its PCR reagent lyophilization production service citing increased demand, as reported by GenomeWeb, and received investment of £1.3 million ($2.0 million) for expansion of its custom service and manufacturing business.